Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.5M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
15.7K
-
Shares change
-
+15.7K
-
Total reported value, excl. options
-
$106K
-
Value change
-
+$106K
-
Number of buys
-
6
-
Price
-
$6.74
Significant Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) as of Q3 2024
6 filings reported holding MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share as of Q3 2024.
Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.7K shares
of 7.5M outstanding shares and own 0.21% of the company stock.
Largest 6 shareholders include GEODE CAPITAL MANAGEMENT, LLC (14.1K shares), NewEdge Advisors, LLC (600 shares), UBS Group AG (512 shares), WELLS FARGO & COMPANY/MN (500 shares), Federation des caisses Desjardins du Quebec (16 shares), and BANK OF AMERICA CORP /DE/ (13 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.